Long-lasting analgesic effect of the psychedelic drug changa : A case report Genis ONA and Sebastian TRONCOSO Journal of Psychedelic Studies, 2019, 3, (1), 7–13. DOI: 10.1556/2054.2019.001 Background and aims : Pain is the most prevalent symptom of a health condition, and it is inappropriately treated in many cases. Here, we present a case report in which we observe a long-lasting analgesic effect produced by changa, a psychedelic drug that contains the psychoactive N,N-dimethyltryptamine and ground seeds of Peganum harmala, which are rich in β-carbolines. Methods : We describe the case and offer a brief review of supportive findings. Results : A long-lasting analgesic effect after [...]
Lire la suiteA single inhalation of vapor from dried toad secretion containing 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) in a naturalistic setting is related to sustained enhancement of satisfaction with life, mindfulness-related capacities, and a decrement of psychopathological symptoms M. V. Uthaug, R. Lancelotta, K. van Oorsouw, K. P. C. Kuypers, N. Mason, J. Rak, A. Šuláková, R. Jurok, M. Maryška, M. Kuchař, T. Páleníček, J. Riba, J. G. Ramaekers Psychopharmacology, 2019 https://doi.org/10.1007/s00213-019-05236-w Abstract Background : 5-methoxy-N,N-dimethyltryptamine (hereinafter referred to as 5-MeO-DMT) is a psychedelic substance found in the secretion from the parotoid glands of the Bufo alvarius toad. Inhalation of vapor from toad secretion containing 5-MeO-DMT has become popular in [...]
Lire la suite5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) used in a naturalistic group setting is associated with unintended improvements in depression and anxiety Alan K. Davis PhD, Sara So MS, Rafael Lancelotta MS, Joseph P. Barsuglia PhD, Roland R. Griffiths PhD The American Journal of Drug and Alcohol Abuse, 2018 DOI: 10.1080/00952990.2018.1545024 Abstract Background : A recent epidemiological study suggested that 5-methoxy-N,Ndimethyltryptamine (5-MeO-DMT) used for spiritual and recreational reasons is associated with subjective improvement in depression and anxiety. Further exploration of the potential psychotherapeutic effects of 5-MeO-DMT could inform future clinical trials. Objectives : We examined self-reported improvement in depression and anxiety among people who use 5-MeODMT in a group setting with [...]
Lire la suiteAnxiety, panic, and hopelessness during and after ritual ayahuasca intake in a woman with generalized anxiety disorder : A case report Rafael G. DOS SANTOS, Flavia L. OSÓRIO, José Alexandre S. CRIPPA and Jaime E. C. HALLAK Journal of Psychedelic Studies, 2017, 1, (1), pp. 35–39 DOI: 10.1556/2054.01.2017.004 Background and aims : Ayahuasca is a dimethyltryptamine- and β-carboline-rich hallucinogenic beverage traditionally used by indigenous groups of Northwest Amazonian for ritual and therapeutic purposes. Animal and human studies suggest that ayahuasca has antidepressant and anxiolytic potentials and has a good safety profile. However, anxiety-like reactions may also occur after ayahuasca intake, although they are rare. Methods [...]
Lire la suiteChemical evidence for the use of multiple psychotropic plants in a 1,000-year-old ritual bundle from South America Melanie J. Miller, Juan Albarracin-Jordan, Christine Moore, and José M. Capriles PNAS June 4, 2019, 116 (23) 11207-11212; first published May 6, 2019 https://doi.org/10.1073/pnas.1902174116 Significance Humans have a long history of using natural resources, especially plants, to induce nonordinary states of consciousness. Imbibing substances derived from plants have been linked to ancient and elaborate knowledge systems and rituals. While archaeological evidence of the consumption of psychotropics, such as alcohol or caffeine, dates back thousands of years, evidence of the use of other psychoactive substances has been more [...]
Lire la suiteAntidepressant effects of a single dose of ayahuasca in patients with recurrent depression: a preliminary report Flavia de L. Osorio, Rafael F. Sanches, Ligia R. Macedo, Rafael G. dos Santos, Joao P. Maia-de-Oliveira, Lauro Wichert-Ana, Draulio B. de Araujo, Jordi Riba, Jose´ A. Crippa, Jaime E. Hallak Revista Brasileira de Psiquiatria, 2015, 37, 13–20 doi:10.1590/1516-4446-2014-1496 Objectives : Ayahuasca (AYA), a natural psychedelic brew prepared from Amazonian plants and rich in dimethyltryptamine (DMT) and harmine, causes effects of subjective well-being and may therefore have antidepressant actions. This study sought to evaluate the effects of a single dose of AYA in six volunteers with a current depressive episode. Methods : [...]
Lire la suitePsychedelic drugs in the treatment of anxiety, depression and addiction Tor-Morten Kvam, Lowan H. Stewart & Ole A. Andreassen Tidsskriftet, Den Norske Legeforening, November 2018 https://www.researchgate.net/publication/332136512 B A C K G R O U N D There is growing interest in the use of psychedelic drugs for the treatment of mental disorders. The drugs are considered safe when administered within a clinical framework. Older studies performed prior to 1970 had methodological shortcomings, but studies in recent years have shown promising results regarding the use of psychedelic drugs in unipolar depression, depression in life-threatening illness, anxiety and addiction. The aim of this literature review is to [...]
Lire la suiteHow do hallucinogens work on the brain? Robin Carhart-Harris, Mendel Kaelen and David Nutt The Psychologist, 2014, 27, 9, 662-665 What do we know about how hallucinogens work on the brain to produce their characteristic subjective effects? This question can be approached from a number of different levels. At the lowest functionally relevant level, how do the hallucinogenic compounds themselves interact with a certain neurotransmitter receptor to alter neuronal activity? Then at the neuronal population level, how does a drug-induced change in neuronal firing interact with the integrated oscillatory activity of large populations of neurons? Finally, how does this all play out at [...]
Lire la suiteIntérêt de la psilocybine, de l’acide lysergique diéthylamide (LSD) et de la diméthyltryptamine (DMT) dans la dépression : une revue de la littérature THÈSE MÉDECINE SPÉCIALISÉE CLINIQUE en Psychiatrie Présentée et soutenue publiquement par Sami SERGENT le 22 février 2019 ANNÉE 2019 (2019 TOU3 1503) Directeur de thèse : Dr François MONTASTRUC JURY Monsieur le Professeur Christophe ARBUS Président Monsieur le Professeur Laurent SCHMITT Assesseur Monsieur le Professeur Nicolas FRANCHITTO Assesseur Monsieur le Docteur François MONTASTRUC Assesseur Madame le Docteur Bénédicte JULLIAN Suppléant Monsieur le Docteur Nicolas NAVARRO membre invité RESUME EN FRANÇAIS : La psilocybine, l’acide lysergique diéthylamide et la diméthyltryptamine sont des psychédéliques agonistes sérotoninergiques. Les sociétés humaines en font usages depuis [...]
Lire la suiteDiscriminative Stimulus Effects of Psychostimulants and Hallucinogens in S()-3,4-Methylene-dioxy-meth amphetamine (MDMA) and R()-MDMA Trained Mice K. S. Murnane, N. Murai, L. L. Howell, and W. E. Fantegrossi THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2009, Vol. 331, No. 2 Copyright © 2009 by The American Society for Pharmacology and Experimental Therapeutics 156174/3525473 JPET 331:717–723, 2009 Preliminary findings from these experiments were previously presented as follows : Murnane K.S., 2008 Expérimentalement Biology Meeting; San Diego, CA. doi:10.1124/jpet.109.156174. ABSTRACT 3,4-Methylenedioxymethamphetamine (MDMA) is a substituted phenethylamine more commonly known as the drug of abuse “ecstasy.” The acute and persistent neurochemical effects of MDMA in the mice are distinct from those in [...]
Lire la suite